Thursday May 25th 2017

Multiple sclerosis patients may benefit from statins, says study

This study suggests, however, that the beneficial effect might be on vascular function rather than the immune system, he added. “After nearly two decades of research, it is immensely gratifying to see this work progress into the clinic to deliver benefits to patients,” he said.MS is an autoimmune disease in which myelin, the fatty insulating material that covers nerve fibres, is destroyed by the body’s own defences. Nerves lacking myelin are not able to transmit messages properly, leading to symptoms ranging from mild tingling or numbness to full blown paralysis.Dr Susan Kohlhaas, head of biomedical research at the MS Society, said: “There are no treatments that can stop the condition from worsening in people with progressive MS. Scientists have worked for years to find a potential treatme…

MedWorm Sponsor Message: Find the best Christmas Sales, Boxing Day Sales and January Sales here.

Link to article:

Multiple sclerosis patients may benefit from statins, says study

Leave a Comment

More from category

MS Study Alert: Share Your Thoughts About MS Research
MS Study Alert: Share Your Thoughts About MS Research

/About-the-Society/News/MS-Study-Alert-Share-Your-Thoughts-About-MS-Resea [Read More]

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS
Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

UK-based specialist pharmaceutical firm Mallinckrodt has begun patient enrolment in the Phase IV OPTIONS clinical trial [Read More]

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS
First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

/About-the-Society/News/First-Results-Announced-from-Second-Phase-III-Tria [Read More]

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows
Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Immune diseases like multiple sclerosis and hemophagocytic lymphohistiocytosis unleash destructive waves of [Read More]

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint
Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

US-based biopharmaceutical firm Celgene has reported positive results from the Phase III RADIANCE clinical trial of [Read More]